Home Cart Sign in  
Chemical Structure| 1253491-42-7 Chemical Structure| 1253491-42-7

Structure of SP-141
CAS No.: 1253491-42-7

Chemical Structure| 1253491-42-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SP-141 is a MDM2 inhibitor. It acts by exerting excellent in-vitro and in-vivo anticancer activity.

Synonyms: AGN-PC-0D106I

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SP-141

CAS No. :1253491-42-7
Formula : C22H16N2O
M.W : 324.38
SMILES Code : COC1=CC2=C(NC3=C2C=CN=C3C4=C5C=CC=CC5=CC=C4)C=C1
Synonyms :
AGN-PC-0D106I
MDL No. :MFCD29059920
InChI Key :AABFWJDLCCDJJN-UHFFFAOYSA-N
Pubchem ID :59620153

Safety of SP-141

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01421511 Skin and Subcutaneous Tissue B... More >>acterial Infections Less << Phase 3 Completed - -
NCT01421511 - Completed - -
NCT00824265 Leukaemia, Lymphocytic, Chroni... More >>c Less << Phase 3 Completed - -
NCT01006135 - Completed - -
NCT02928445 Dementia With Lewy Bodies Phase 2 Phase 3 Terminated(Intepirdine did not... More >> meet its primary efficacy endpoints in the lead-in study RVT-101-2001.) Less << - -
NCT00958841 - Terminated(Slow recruitment ra... More >>te into this study with rare tumors of neuroendocrine origin (enrollment issues)) Less << - -
NCT01006135 - Completed - -
NCT02586909 Alzheimer's Disease Phase 3 Terminated(Intepirdine did not... More >> meet its primary efficacy endpoints in lead-in study RVT-101-3001.) Less << - -
NCT02669433 Dementia With Lewy Bodies Phase 2 Completed - -
NCT00958841 Pancreatic Neoplasm ... More >> Pituitary Neoplasm Nelson Syndrome Ectopic ACTH Syndrome Less << Phase 2 Terminated(Slow recruitment ra... More >>te into this study with rare tumors of neuroendocrine origin (enrollment issues)) Less << - -
NCT00599339 - Completed - -
NCT02585934 - Completed - -
NCT02585934 Alzheimer's Disease Phase 3 Completed - -
NCT00955357 - Completed - -
NCT00955357 Partial Epilepsies Phase 4 Completed - -
NCT01300819 Idiopathic Parkinson's Disease Phase 4 Completed - -
NCT01102621 - Completed - Brazil ... More >> Hospital A C Camargo São Paulo, SP, Brazil, 01509-900 Less <<
NCT00824265 - Completed - -
NCT00599339 - Completed - -
NCT01300819 - Completed - -
NCT01098162 - Completed - -
NCT01098162 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.08mL

0.62mL

0.31mL

15.41mL

3.08mL

1.54mL

30.83mL

6.17mL

3.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories